false
0001123494
0001123494
2024-03-07
2024-03-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2024
HARVARD BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-33957 |
04-3306140 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
84 October Hill Road
Holliston, MA 01746
(Address of Principal Executive Offices) (Zip Code)
(508) 893-8999
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: |
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.01 par value |
HBIO |
The NASDAQ Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 7, 2024, Harvard Bioscience, Inc. (the “Company”) issued a press
release announcing financial results for the three and twelve months ended December 31, 2023, and the details of a related conference
call to be held at 8:00 AM ET on March 7, 2024. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached
hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HARVARD BIOSCIENCE, INC. |
|
|
|
|
Date: March 7, 2024 |
By: |
/s/ Jennifer Cote |
|
|
|
Jennifer Cote |
|
|
|
Chief Financial Officer |
|
|
|
Exhibit 99.1
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
| · | Q4 Revenues of $28.2 million |
| · | Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) |
| · | Q4 operating income of $0.3 million, adjusted operating income of $3.3 million |
| · | Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage |
HOLLISTON, Mass., March 7, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience,
Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.
Jim Green, Chairman and CEO said, “Our fourth quarter
revenue was down a modest 1% compared to the prior year quarter in a challenging APAC marketplace. Revenue included a net reduction of
approximately $0.9 million of remaining discontinued products from prior year. We saw significant gross margin expansion and continued
our relentless focus on enhancing the product portfolio. At the same time, we introduced exciting new products which we expect to lead
to future growth.”
Green continued, “We remain focused on solidifying our
base business and expanding recurring revenue by introducing new products, services, and consumables. Our latest product introductions
are penetrating exciting high growth adjacencies in bioproduction and advanced cell and organoid applications where we expect to see
adoption in research, pharma, and biotech, in addition to high volume industrial applications.”
Financial
Results Summary | |
Three
Months Ended December 31, | |
Year
Ended December 31, |
(unaudited,
$ in millions except per share data) | |
2023 | |
2022 | |
2023 | |
2022 |
Revenues | |
$ | 28.2 | | |
$ | 28.4 | | |
$ | 112.3 | | |
$ | 113.3 | |
Gross margin | |
| 58.0 | % | |
| 55.7 | % | |
| 58.9 | % | |
| 53.7 | % |
Operating income (loss) (GAAP) | |
$ | 0.3 | | |
$ | (0.5 | ) | |
$ | 1.9 | | |
$ | (6.9 | ) |
Adjusted operating income | |
$ | 3.3 | | |
$ | 3.4 | | |
$ | 13.1 | | |
$ | 9.5 | |
Net loss (GAAP) | |
$ | (1.8 | ) | |
$ | (1.7 | ) | |
$ | (3.4 | ) | |
$ | (9.5 | ) |
Diluted loss per share (GAAP) | |
$ | (0.04 | ) | |
$ | (0.04 | ) | |
$ | (0.08 | ) | |
$ | (0.23 | ) |
Diluted adjusted earnings per share | |
$ | 0.04 | | |
$ | 0.04 | | |
$ | 0.14 | | |
$ | 0.12 | |
Adjusted EBITDA | |
$ | 3.6 | | |
$ | 3.7 | | |
$ | 14.6 | | |
$ | 10.8 | |
Adjusted EBITDA margin | |
| 13.0 | % | |
| 13.0 | % | |
| 13.0 | % | |
| 9.6 | % |
Cash flow provided by operations | |
$ | 4.3 | | |
$ | 2.7 | | |
$ | 14.0 | | |
$ | 1.2 | |
Debt, including unamortized deferred financing costs | |
| | | |
| | | |
$ | 36.6 | | |
$ | 46.8 | |
Net debt (non-GAAP) | |
| | | |
| | | |
$ | 32.8 | | |
$ | 43.2 | |
Net leverage ratio (non-GAAP) (1) | |
| | | |
| | | |
| 2.3 | | |
| 4.0 | |
(1) | Net leverage ratio is defined as our net debt divided by our trailing twelve-month
adjusted EBITDA as defined in our credit agreement. For more information, please refer to the reconciliation of GAAP to non-GAAP financial
measures included in the appendix to this press release. |
Fourth Quarter 2023 Highlights
For the fourth quarter of fiscal 2023, the Company reported
revenues of $28.2 million compared to $28.4 million in the fourth quarter of fiscal 2022 and included a net reduction of $0.9 million
from discontinued products from the fourth quarter of 2022. Gross margin for the three months ended December 31, 2023 was 58.0% compared
with 55.7% in the comparable quarter of the prior year.
Net loss for the fourth quarter of 2023 was $(1.8) million and
included an unfavorable impact of a $(0.3) million unrealized loss on marketable securities. This compares to net loss of $(1.7) million
in the fourth quarter of 2022. Adjusted EBITDA for the fourth quarter of 2023 was $3.6 million, compared to $3.7 million in the fourth
quarter of the prior year.
Cash provided by operations for the fourth quarter of 2023
was $4.3 million compared to $2.7 million in the same period last year. Debt was reduced by $2.3 million during the quarter.
Year Ended December 31, 2023 Highlights
For the year ended December 31, 2023, revenues were $112.3
million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from
discontinued products compared to 2022. Gross margin was 58.9% compared to 53.7% in the prior year. Gross margins in
the prior year included the impact of a $1.5 million inventory charge related to the
discontinued products.
Full year net loss was $(3.4) million, including an unfavorable
$(0.6) million unrealized loss on marketable securities, compared to a net loss of $(9.5) million in the prior year, which included the
aforementioned inventory charges. Adjusted EBITDA was $14.6 million, compared to $10.8 million in 2022.
Cash provided by operations in the year was $14.0 million
compared to $1.2 million in the prior year. Debt was reduced by $10.5 million during the
year.
2024 Guidance
For the full year 2024 we expect flat to modest revenue growth. We expect
weakness in the first half versus a strong prior year comparison. We also expect strong second half growth versus both first half of
2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions. In
addition, we expect further gross margin expansion in the full year 2024 to approximately 60% compared to 59% in 2023 and adjusted EBITDA
margin improving to the mid-teens compared to 13% in 2023.
This press release includes certain financial information presented
on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please
see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.
Webcast and Conference Call Details
In conjunction with this announcement, Harvard Bioscience will be hosting
a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted
to our Investor Relations website shortly before the webcast begins.
Analysts who want to join the call and ask a question must register here.
Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who want to join the audio-only webcast should go to our events
and presentations on the investor website here.
Use of Non-GAAP Financial Information
In this press release, we have included non-GAAP financial
information, including one or more of adjusted operating income (loss), adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin,
diluted adjusted earnings (loss) per share, net debt and net leverage ratio. We believe that this non- GAAP financial information provides
investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial
measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations
of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, litigation settlement,
restructuring and other costs, unrealized gain/loss on equity securities, income taxes, and. the tax impact of the reconciling items.
Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is
useful to investors and financial analysts in assessing the Company’s operating performance.
Non-GAAP historical financial statement information included
herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press
release.
With respect to non-GAAP forward-looking measures, we provide
an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable
of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook
statements to vary materially from our GAAP results.
The non-GAAP financial information provided in this press
release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with
GAAP and may be different than other companies’ non-GAAP financial information.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer
and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical
and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned
academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations.
With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers
around the world.
For more information, please visit our website at www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the
meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may
be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking
statements include, but are not limited to, information concerning expected future financial and operational performance including revenues,
gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company’s
market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown
uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that
could cause the Company’s actual results to differ materially from those described its forward-looking statements include those
described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in
the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s
expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking
statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
Harvard Bioscience, Inc.
Investor Relations
investors@harvardbioscience.com
(508) 893-3120
|
|
|
|
HARVARD BIOSCIENCE, INC. |
|
|
Consolidated Statements of Operations |
|
|
(unaudited, in thousands, except per share data) |
|
|
| |
| |
| |
| |
|
|
|
| |
Three Months Ended | |
Year Ended |
|
|
| |
December 31, 2023 | |
December 31, 2022 | |
December 31, 2023 | |
December 31, 2022 |
|
|
| |
| |
| |
| |
|
|
|
Revenues | |
$ | 28,153 | | |
$ | 28,427 | | |
$ | 112,250 | | |
$ | 113,335 | |
|
|
Cost of revenues | |
| 11,828 | | |
| 12,594 | | |
| 46,179 | | |
| 52,516 | |
|
|
Gross profit | |
| 16,325 | | |
| 15,833 | | |
| 66,071 | | |
| 60,819 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
|
|
Sales and marketing expenses | |
| 6,220 | | |
| 5,948 | | |
| 24,108 | | |
| 25,041 | |
|
|
General and administrative expenses | |
| 5,286 | | |
| 5,863 | | |
| 22,780 | | |
| 24,493 | |
|
|
Research and development expenses | |
| 3,150 | | |
| 2,849 | | |
| 11,764 | | |
| 12,329 | |
|
|
Amortization of intangible assets | |
| 1,387 | | |
| 1,630 | | |
| 5,525 | | |
| 6,122 | |
|
|
Litigation settlement | |
| - | | |
| - | | |
| - | | |
| (233 | ) |
|
|
Total operating expenses | |
| 16,043 | | |
| 16,290 | | |
| 64,177 | | |
| 67,752 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Operating income (loss) | |
| 282 | | |
| (457 | ) | |
| 1,894 | | |
| (6,933 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Other (expense) income: | |
| | | |
| | | |
| | | |
| | |
|
|
Interest expense | |
| (794 | ) | |
| (900 | ) | |
| (3,591 | ) | |
| (2,548 | ) |
|
|
Unrealized loss on equity securities | |
| (259 | ) | |
| - | | |
| (632 | ) | |
| - | |
|
|
Other (expense) income, net | |
| (332 | ) | |
| 465 | | |
| (227 | ) | |
| 302 | |
|
|
Total other expense | |
| (1,385 | ) | |
| (435 | ) | |
| (4,450 | ) | |
| (2,246 | ) |
|
|
Loss before income taxes | |
| (1,103 | ) | |
| (892 | ) | |
| (2,556 | ) | |
| (9,179 | ) |
|
|
Income tax expense | |
| 715 | | |
| 774 | | |
| 859 | | |
| 337 | |
|
|
Net loss | |
$ | (1,818 | ) | |
$ | (1,666 | ) | |
$ | (3,415 | ) | |
$ | (9,516 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Loss per common share: | |
| | | |
| | | |
| | | |
| | |
|
|
Basic and diluted | |
$ | (0.04 | ) | |
$ | (0.04 | ) | |
$ | (0.08 | ) | |
$ | (0.23 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Weighted-average common shares: | |
| | | |
| | | |
| | | |
| | |
|
|
Basic and diluted | |
| 42,710 | | |
| 42,102 | | |
| 42,420 | | |
| 41,413 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
|
|
|
HARVARD BIOSCIENCE, INC. |
|
|
Condensed Consolidated Balance Sheets |
|
|
(unaudited, in thousands) |
|
|
| |
| |
|
|
|
| |
December 31, |
|
|
| |
2023 | |
2022 |
|
|
Assets | |
| |
|
|
|
Cash and cash equivalents | |
$ | 4,283 | | |
$ | 4,508 | |
|
|
Accounts receivable, net | |
| 16,099 | | |
| 16,705 | |
|
|
Inventories | |
| 24,716 | | |
| 26,439 | |
|
|
Other current assets | |
| 3,940 | | |
| 3,472 | |
|
|
Total current assets | |
| 49,038 | | |
| 51,124 | |
|
|
Property, plant and equipment | |
| 3,981 | | |
| 3,366 | |
|
|
Goodwill and other intangibles | |
| 73,101 | | |
| 77,274 | |
|
|
Other long-term assets | |
| 11,246 | | |
| 13,596 | |
|
|
Total assets | |
$ | 137,366 | | |
$ | 145,360 | |
|
|
| |
| | | |
| | |
|
|
Liabilities and Stockholders' Equity | |
| | | |
| | |
|
|
Current portion, long-term debt | |
$ | 5,859 | | |
$ | 3,811 | |
|
|
Other current liabilities | |
| 20,683 | | |
| 19,438 | |
|
|
Total current liabilities | |
| 26,542 | | |
| 23,249 | |
|
|
Long-term debt, net | |
| 30,704 | | |
| 43,013 | |
|
|
Other long-term liabilities | |
| 7,046 | | |
| 6,878 | |
|
|
Stockholders’ equity | |
| 73,074 | | |
| 72,220 | |
|
|
Total liabilities and stockholders’ equity | |
$ | 137,366 | | |
$ | 145,360 | |
|
|
| |
| | | |
| | |
|
|
|
|
|
HARVARD BIOSCIENCE, INC. |
|
|
Condensed Consolidated Statements of Cash Flows |
|
|
(unaudited, in thousands) |
|
|
| |
| |
| |
| |
|
|
|
| |
Three Months Ended | |
Year Ended |
|
|
| |
December 31, 2023 | |
December 31, 2022 | |
December 31, 2023 | |
December 31, 2022 |
|
|
Cash flows from operating activities: | |
| | | |
| | | |
| | | |
| | |
|
|
Net loss | |
$ | (1,818 | ) | |
$ | (1,666 | ) | |
$ | (3,415 | ) | |
$ | (9,516 | ) |
|
|
Adjustments to operating cash flows | |
| 3,732 | | |
| 2,787 | | |
| 12,843 | | |
| 7,952 | |
|
|
Changes in operating assets and liabilities | |
| 2,389 | | |
| 1,558 | | |
| 4,600 | | |
| 2,716 | |
|
|
Net cash provided by operating activities | |
| 4,303 | | |
| 2,679 | | |
| 14,028 | | |
| 1,152 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Cash flows from investing activities: | |
| | | |
| | | |
| | | |
| | |
|
|
Additions to property, plant and equipment | |
| (830 | ) | |
| (235 | ) | |
| (1,788 | ) | |
| (1,590 | ) |
|
|
Acquisition of intangible assets | |
| (231 | ) | |
| - | | |
| (523 | ) | |
| - | |
|
|
Proceeds from sale of product line | |
| - | | |
| - | | |
| 512 | | |
| - | |
|
|
Net cash used in investing activities | |
| (1,061 | ) | |
| (235 | ) | |
| (1,799 | ) | |
| (1,590 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Cash flows from financing activities: | |
| | | |
| | | |
| | | |
| | |
|
|
Borrowing from revolving line of credit | |
| 1,000 | | |
| - | | |
| 4,500 | | |
| 7,800 | |
|
|
Repayment of revolving line of credit | |
| (2,500 | ) | |
| (1,750 | ) | |
| (10,950 | ) | |
| (6,400 | ) |
|
|
Repayment of term debt | |
| (750 | ) | |
| (750 | ) | |
| (4,091 | ) | |
| (3,186 | ) |
|
|
Proceeds from exercise of employee stock options and purchases | |
| 206 | | |
| 231 | | |
| 930 | | |
| 577 | |
|
|
Taxes paid related to net share settlement of equity awards | |
| (2,072 | ) | |
| (461 | ) | |
| (2,523 | ) | |
| (1,628 | ) |
|
|
Net cash used in financing activities | |
| (4,116 | ) | |
| (2,730 | ) | |
| (12,134 | ) | |
| (2,837 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Effect of exchange rate changes on cash and cash equivalents | |
| (183 | ) | |
| (350 | ) | |
| (320 | ) | |
| (38 | ) |
|
|
Decrease in cash and cash equivalents | |
| (1,057 | ) | |
| (636 | ) | |
| (225 | ) | |
| (3,313 | ) |
|
|
Cash and cash equivalents at the beginning of period | |
| 5,340 | | |
| 5,144 | | |
| 4,508 | | |
| 7,821 | |
|
|
Cash and cash equivalents at the end of period | |
$ | 4,283 | | |
$ | 4,508 | | |
$ | 4,283 | | |
$ | 4,508 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
|
|
|
HARVARD BIOSCIENCE, INC. |
|
|
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) |
|
|
(in thousands, except per share data) |
|
|
| |
Three Months Ended | |
Year Ended |
|
|
| |
December 31, 2023 | |
December 31, 2022 | |
December 31, 2023 | |
December 31, 2022 |
|
|
| |
| |
| |
| |
|
|
|
| |
| |
| |
| |
|
|
|
GAAP operating income (loss) | |
$ | 282 | | |
$ | (457 | ) | |
$ | 1,894 | | |
$ | (6,933 | ) |
|
|
Stock-based compensation | |
| 1,382 | | |
| 1,010 | | |
| 5,000 | | |
| 4,411 | |
|
|
Acquired asset amortization | |
| 1,394 | | |
| 1,648 | | |
| 5,561 | | |
| 6,236 | |
|
|
Restructuring & other | |
| 207 | | |
| 1,168 | | |
| 656 | | |
| 6,016 | |
|
|
Litigation settlement | |
| - | | |
| - | | |
| - | | |
| (233 | ) |
|
|
Adjusted operating income | |
$ | 3,265 | | |
$ | 3,369 | | |
$ | 13,111 | | |
$ | 9,497 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Operating margin | |
| 1.0 | % | |
| -1.6 | % | |
| 1.7 | % | |
| -6.1 | % |
|
|
Adjusted operating margin | |
| 11.6 | % | |
| 11.9 | % | |
| 11.7 | % | |
| 8.4 | % |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
GAAP net loss | |
$ | (1,818 | ) | |
$ | (1,666 | ) | |
$ | (3,415 | ) | |
$ | (9,516 | ) |
|
|
Stock-based compensation | |
| 1,382 | | |
| 1,010 | | |
| 5,000 | | |
| 4,411 | |
|
|
Acquired asset amortization | |
| 1,394 | | |
| 1,648 | | |
| 5,561 | | |
| 6,236 | |
|
|
Restructuring & other | |
| 207 | | |
| 1,068 | | |
| 253 | | |
| 5,836 | |
|
|
Litigation settlement | |
| - | | |
| - | | |
| - | | |
| (233 | ) |
|
|
Unrealized loss on equity securities | |
| 258 | | |
| - | | |
| 632 | | |
| - | |
|
|
Income taxes | |
| 315 | | |
| (281 | ) | |
| (1,604 | ) | |
| (1,689 | ) |
|
|
Adjusted net income | |
| 1,738 | | |
| 1,779 | | |
| 6,427 | | |
| 5,045 | |
|
|
Depreciation | |
| 386 | | |
| 314 | | |
| 1,440 | | |
| 1,338 | |
|
|
Interest and other expense, net | |
| 1,126 | | |
| 536 | | |
| 4,221 | | |
| 2,426 | |
|
|
Adjusted income taxes (1) | |
| 400 | | |
| 1,054 | | |
| 2,463 | | |
| 2,026 | |
|
|
Adjusted EBITDA | |
$ | 3,650 | | |
$ | 3,683 | | |
$ | 14,551 | | |
$ | 10,835 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Adjusted EBITDA margin | |
| 13.0 | % | |
| 13.0 | % | |
| 13.0 | % | |
| 9.6 | % |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Diluted loss per share (GAAP) | |
$ | (0.04 | ) | |
$ | (0.04 | ) | |
$ | (0.08 | ) | |
$ | (0.23 | ) |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Diluted adjusted earnings per share | |
$ | 0.04 | | |
$ | 0.04 | | |
$ | 0.14 | | |
$ | 0.12 | |
|
|
Weighted-average common shares: | |
| | | |
| | | |
| | | |
| | |
|
|
Diluted GAAP | |
| 42,710 | | |
| 42,102 | | |
| 42,420 | | |
| 41,413 | |
|
|
Diluted Adjusted | |
| 44,819 | | |
| 42,740 | | |
| 44,361 | | |
| 42,682 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| December 31, 2023 | | |
| December 31, 2022 | |
|
|
Debt, including unamortized deferred financing costs | |
| | | |
| | | |
$ | 36,563 | | |
$ | 46,824 | |
|
|
Unamortized deferred financing costs | |
| | | |
| | | |
| 560 | | |
| 840 | |
|
|
Cash and cash equivalents | |
| | | |
| | | |
| (4,283 | ) | |
| (4,508 | ) |
|
|
Net debt | |
| | | |
| | | |
$ | 32,840 | | |
$ | 43,156 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
Net leverage ratio (2) | |
| | | |
| | | |
| 2.3 | | |
| 4.0 | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
(1) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise. |
|
|
| |
| | | |
| | | |
| | | |
| | |
|
|
(2) Net leverage ratio is defined herein as net debt divided by our trailing twelve months adjusted EBITDA as defined in our credit agreement and as shown above. |
|
|
| |
|
v3.24.0.1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024